The round was led by CPMG, with participation from Vivo Capital, First Round Capital, Manta Ray Ventures, Alumni Ventures, and Asahi Kasei. The company is improving the health, vitality, and longevity of human beings through bioengineering and will deploy this funding to dramatically grow its proprietary bone marrow bank, build on existing clinical trials, and accelerate new product development.

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Founded in 2016, the company is led by Kevin Caldwell, its CEO, Co-Founder & President, and Erik Woods, its Chief Science Officer, Co-Founder & EVP. Ossium Health is an FDA-Registered Tissue Bank, is accredited by the Commission on Office Laboratory Accreditation (COLA), and its laboratory is certified under the Clinical Laboratory Improvement Amendment (CLIA).